Nasus Pharma

Company Overview

Snapshot

Founded in May 2019 by Udi Gilboa and Dr. Dalia Meggido, Nasus Pharma operates with 1–10 employees. The company has raised $25 million across two funding rounds. In August 2025, Nasus Pharma completed its Initial Public Offering on the NYSE.

Business overview

Nasus Pharma is a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based intranasal products. Leveraging its microsphere technology, the company creates solutions for acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio includes programs for intranasal naloxone and intranasal epinephrine, serving the pharmaceutical and healthcare industries with non-invasive drug delivery methods.

Strategic signal

Nasus Pharma recently announced positive topline data from its Phase 2 clinical study of NS002 Intranasal Epinephrine Powder in March 2026. The study demonstrated significantly superior and faster epinephrine delivery compared to EpiPen®, achieving an accelerated speed to therapeutic threshold. This outcome is a strong validation of the company's core technology and its potential to address critical emergency medical needs, signaling significant progress towards pivotal studies and commercialization for investors.

Company Intelligence Q&A

When did Nasus Pharma go public?

Nasus Pharma completed its Initial Public Offering (IPO) on the NYSE in August 2025, pricing the offering at $10 million.

What was a key finding from the NS002 Phase 2 clinical study?

In March 2026, Nasus Pharma announced positive topline data from its Phase 2 clinical study of NS002 Intranasal Epinephrine Powder, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen® with an accelerated speed to therapeutic threshold.

Has Nasus Pharma recently strengthened its leadership team?

In November 2025, Nasus Pharma strengthened its leadership team by appointing Eyal Rubin as Executive Vice President and Chief Financial Officer.

What was the outcome of the preclinical study for Intranasal Ondansetron (NS003)?

In June 2026, Nasus Pharma announced positive results from a preclinical pharmacokinetic and safety study of Intranasal Ondansetron (NS003).

What is the latest leadership change at Nasus Pharma?

In July 2026, Nasus Pharma appointed Brendan P. O'Grady, a pharmaceutical industry veteran, as its new Chief Executive Officer to lead strategic growth.